LiaGoreMD

PubMed

• Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed-rearranged acute lymphoblastic leukemia: Children's Oncol...
  Erin M Guest, John A Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J Carroll
  Haematologica. 2024-12-01
• Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab.
  Elias J Jabbour, Hagop M Kantarjian, Nicola Goekbuget, Bijal D Shah, Sabina Chiaretti
  Blood Cancer Journal. 2024-11-19
• Pediatric Exclusivity Revenues for Cancer Drugs.
  Ameet Sarpatwari, Liam Bendicksen, Douglas S Hawkins, Lia Gore, Florence T Bourgeois
  JAMA Pediatrics. 2024-11-11

Journal Articles

• Phase I Combination Study of Trabectedin and Capecitabine in Patients With Advanced Malignancies  
  Gore L, Rivera E, Basche M, Moulder SL, LaVallee K, Li J, Sarah Eppers S, Grolnic S, O'Bryant CL, Cleere D, Elsayed YA, Eckhardt SG, Investigational New Drugs, 1/1/2011
• A phase I study of weekly R1507 - a human monoclonal antibody insulin-like growth factor receptor-1 antagonist - in patients with advanced solid tumors  
  Kurzrock R, Mitta AC, Ainser J, Eid JE, Greig G, Habben K, McCarthy CD, Eckhardt SG, Gore L, Clinical Cancer Research, 1/6/2010
• Challenges and Controversies in Early-phase Pediatric Oncology Clinical Trials: Who, How, Why, and What ?  
  Gore L and Eckhardt SG, ASCO News and Forum, 1/1/2009
• A phase I study of immunotoxins HD37 and RFB4 (Combotox) in pediatric patients with refractory B-lineage leukemia  
  Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel P, Gaynon P, Aquino V, Vitetta E, Schindler J, Journal of Pediatric Hematology Oncology, 1/1/2009
• Successful cord blood stem cell transplantation for sickle cell anemia from an HLA-identical sibling: Implications for comprehensive care  
  Gore L, Lane P, Quinones RR, Giller RH, Journal of Pediatric Hematology/Oncology, 1/1/2000
• Demodicidiosis in childhood acute lymphoblastic leukemia: an opportunistic infection occurring with immunosuppression  
  Ivy SP, Mackall CL, Gore L, Gress RE, Hartley AH, Journal of Pediatrics, 1/1/1995
• Join now to see all

Abstracts/Posters

• Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...
  Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
  Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
  Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• ZUMA-4: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 (anti-CD19 Chimeric Antigen Receptor [CAR] T Cells) in Pediatric and Adolescent Sub...
  Sender L, Wayne AS, Lee DW, Huynh V, Handgretinger R, Brown P, Gore L, Rosenthal J, Bot A, Rossi J, Jiang Y, Navale L, Stout S, Aycock J, Wiezorek J, Jain R, PanPacific Lymphoma Conference, Koloa, HI, 1/1/2016
• Addition of FLT3 inhibitor lestaurtinib to post-induction chemotherapy does not improve outcomes in MLL-rearranged infant acute lymphoblastic leukemia (ALL): AALL0631...
  Brown P, Kairalla J, Wang C, Dreyer Z, Salzer W, Sorenson M, Borowitz M, Carroll A, Heerema N, Rao K, Gore L, Devidas M, Carroll W, Winick N, Raetz E, Loh M, Hunger S,..., International Society of Pediatric Oncology Annual Meeting, Dublin, Ireland, 1/1/2016
• ZUMA4: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTEC19 AntiCD19 Chimeric Antigen Receptor (CAR) T Cells In Pediatric and Adolescent Patients...
  Huynh V, Wayne AS, Sender L, Lee DW, Handgretinger R, Pieters R, Michel G, Brown P, Gore L, Rosenthal J, Bot A, Rossi JM, Jiang Y, Navale L, Stout S, Aycock J, Wiezore..., 41st Congress of the European Society for Medical Oncology (ESMO), Copenhagen, Denmark, 1/1/2016
• A phase I dose escalation study of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous (IV) administration in patients with advanced solid tumors
  Razak A, Gore L, Britten C, Miller W, Uy G, Nichols G, Middleton S, Blotner S, Zhi J, Jukofsky L, Pierceall W, Higgins B, Chen L-C, AACR/NCI/EORTC Meeting on Molecular Targets and Cancer Therapeutics, Munich, Germany, 1/1/2016
• Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-induced Remission in Pediatric Patients With Relapsed/Refractory (r/r) B-Precursor...
  Handgretinger R, Gore L, Zugmaier G, Locatelli F, Zwaan CM, Bhojwani D, Bader P, O'Brien MO, Trippett TM, Brethon B, Rizzari C,Schlegel PG,Michel G, Barnette P, Messin..., American Society of Bone Marrow Transplant/International Bone Marrow Transplant Tandem Meetings, San Diego, CA, 1/1/2015
• Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymph...
  Burke M, Devidas M, Chen S, Gore L, Larsen E, Hilden JM, Loh ML, Winick NJ, Carroll WL, Raetz EA, Hunger S, Salzer WL, J Clin Oncol, 1/1/2015
• The First Reported Results of AG-120, a First-in-Class, Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of Patients with Advanced IDH1-Mutant Solid Tum...
  Burris H, Mellinghoff I, Maher E, Wen P, Beeram M, Touat M, Faris J, Azad N, Cloughesy T, Gore L, Trent J, Von Hoff D, Goldwasser M, Fan B, Wu B, Agresta, Molecular Cancer Therapeutics, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 1/1/2015
• Phase I trial of the mTOR inhibitor everolimus given in combination with multiagent chemotherapy in relapsed childhood acute lymphoblastic leukemia
  Place AE, Pikman Y, Stevenson K, Cooper TM, Gore L, Hijiya N, Loh ML, Pauly M, Sulis ML, Neuberg DS, Stegmaier K, Sallan SE, Silverman LB, Blood, American Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
• Incidence of allergic reactions to pegasparagase (PEG) administered intramuscularly versus intravenously (IM vs IV) in children and young adults with high risk B-lymph...
  Salzer W, Burke MJ, Larsen EC, Chen S, Gore L, Hilden JM, Loh ML, Raetz E, Winick NJ, Carroll WL, Devidas M, Hunger SP, Blood, American Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
• Preliminary report of the Phase I Study of the DOT1L inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure, and Evidence of Target...
  Shukla N, O'Brien MM, Silverman LB, Pauly M, Wetmore C, Loh ML, Whitlock JA, Brown P, Thomson B, Blakemore SJ, Daigle SR, Pimentel P, Waters NJ, Kristov AV, Koche R, A..., Blood, American Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
• Induction mortality and its association with Invasive Fungal Infections (IFI) in Children and Young Adults with High Risk (HR) B-lymphoblastic Leukemia (B-ALL): Early...
  Salzer WL, Burke M, Devidas M, Gore L, Larsen E, Zaoutis T, Fisher B, Steinbach W, Hilden J, Loh ML, Winick N, Carroll WL, Raetz E, Sung L, Hunger SP, American Society of Pediatric Hematology/Oncology Annual Meeting, Chicago, IL, 1/1/2014
• Blinatumomab In Pediatric Patients With Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (Bcp-All): A Phase 1/2 Study
  Whitlock J, von Stackelberg A, Handgretinger R, Locatelli F, Rizzari C, Trippett TM,Borkhardt A, O'Brien MM, Rheingold SR, Gore L, International Pediatric Oncology Society (SIOP) meetings, Toronto, Canada, 1/1/2014
• Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): P...
  Mauz-Korholz C, Neville K, Rosolen A, Landman-Parker J, Aladjidi N, Beishuizen A, Daw S, Gore L, Franklin ARK, Fasanmade A, Wang J, J. Sachs J, Locatelli F, German Society of Pediatric Oncology and Hematology, Leipzig, Germany, 1/1/2014
• A Phase I Study of Lurbinectedin (PM01183) Administered on Days (D)1 & 8 Every 3 Weeks (q3wk) in Patients (pts) with Solid Tumors
  Ratain MJ, Gore L, Szyldergemajn S, Diamond J, Geary D, Fernandez-Teruel C, Soto-Matos A, Sharma M, Jimeno A, 26th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics, Barcelona, Spain, 1/1/2014
• A Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
  Gore L, Locatelli F, Zugmaier G, Zwaan CM, Bhojwani D, Handgretinger R, Bader P, O'Brien M, Trippett TM, Brethon B, Rizzari C, DuBois SG, Schlegel PG, Michel G, Barnet..., American Society of Hematology Annual Meeting, San Francisco, CA, 1/1/2014
• Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment
  von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Zwaan CM, Bhojwani D, DuBois SG, Bader P, Borkhardt A, O'Brien MM, Rheingold SR, C..., American Society of Hematology Annual Meeting, San Francisco, CA, 1/1/2014
• Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma...
  Whitlock JA, Gore L, American Society of Hematology Annual Meeting, San Francisco, CA, 1/1/2014
• Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therape...
  Burke MJ, Gore L, Sposto R, Bhojwani D, Chang WH, DuBois SG, Gaynon PS, Glade-Bender J, Heym KM, Huynh VT, Sulis ML, Pollard JA, Verma A, PA Brown, American Society of Hematology Annual Meeting, San Francisco, CA, 1/1/2014
• A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
  Pollyea DA, Gore L, Gutman JA, Eckhardt SG, Hagelstrom N, Coutre S, Byrd J, Therapeutically Applicable Targets (TAT) Meeting, Paris, France, 1/1/2013
• A Phase I Study of Ridaforolimus (MK-8669) in Pediatric Patients with Advanced Solid Tumors
  Pearson ADJ, Frappaz D, Marshall L, Angelini P, Gatz S, DuBois S, Gore L, Doz F, Iannone R, Geschwindt R, Georger B, Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, Chicago, IL, 1/1/2013
• A phase I study of the anti-insulin like growth factor type I receptor (IGF-1R) antibody dalotuzumab in pediatric patients with advanced solid tumors
  Frappaz D, McGregor LM, Pearson ADJ, Gore L, DuBois SG, Aerts I, Iannone R, Geschwindt R, VanSchanke A, Wang R, Geoerger B, Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, Chicago, IL, 1/1/2013
• Phase 1/2 study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory systemic anaplastic large-cell lymphoma (sALCL) or Hodgkin lymphoma (HL)...
  Neville K, Gore L, Mauz-Körholz C, Rosolen A, Landman-Parker J, Sanchez de Toledo J, Beishuizen A, Franklin ARK, Fasanmade A, Wang J, Huebner D, Locatelli F, Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, Chicago, IL, 1/1/2013
• Join now to see all

Lectures

• Expanding Horizons for Immunotherapy in Pediatric Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Medically-supported Camp Experiences on Children with Life-threatening Illnesses 
  Denver, CO - 1/1/2016
• The Future of Cancer Treatments: Advances in Childhood Leukemia 
  University of Colorado Anschutz Medical Campus, Aurora, CO - 1/1/2016
• Impact of Philanthropy on Advances in Childhood Cancer 
  Copper Mountain, CO - 1/1/2016
• Emerging Insights into What Might Come Next for the Treatment of Refractory Pediatric Leukemias: CARTs, BITEs, and other strange names 
  Lisbon, Portugal - 1/1/2016
• North American Portfolio for Relapsed ALL 
  Brussels, Belgium - 1/1/2016
• Approaches to Relapsed ALL in Childhood 
  Glasgow, Scotland - 1/1/2016
• New Agents in North America for ALL 
  Athens, Greece - 1/1/2016
• Platforms for Progress 
  Aspen, CO - 1/1/2015
• Informed Consent: Protections and Obstacles - Children as Research Subjects 
  University of Colorado, Aurora, CO - 1/1/2015
• Blinatumomab Development: From phase I to marketing approval in less than three years 
  Memorial Sloan-Kettering Cancer Center, New York, NY - 1/1/2015
• Blinatumomab Pediatric Data 
  1/1/2015
• CARTs, BITEs, and other strange names in the treatment of Refractory Leukemias 
  Toronto, ON, Canada - 1/1/2015
• Everolimus on the R3 Backbone: Report of a DFCI Consortium trial for Relapsed Pediatric ALL 
  Signtuna, Sweden - 1/1/2015
• DOT1L inhibition, Epigenetic Manipulation, CAR-Tcells, and Targeting in Relapsed Pediatric B-lineage ALL 
  Signtuna, Sweden - 1/1/2015
• B-raf and ALK: Emerging targets in pediatric cancer therapy across disease silos 
  Chicago, IL - 1/1/2015
• Blinatumomab in Childhood ALL 
  Zurich, Switzerland - 1/1/2015
• Treatment for Relapsed ALL 
  Dallas, TX - 1/1/2015
• EPZ5676 Clinical Trial Report 
  Toronto, ON, Canada - 1/1/2015
• Immune-based Therapies for Refractory Pediatric Leukemia: blinatumomab 
  1/1/2015
• Use of Novel Treatments for Childhood ALL 
  Fort Lauderdale, FL - 1/1/2015
• Why I became a Pediatric Oncologist 
  University of Colorado School of Medicine, Denver, CO - 1/1/2014
• Join now to see all